Shares of Cellectis S.A. plunged 31% in active premarket trade Tuesday, after the company said two phase 1 trials of its leukemia treatment were put on hold after a fatality was reported. Volume was 194,000 shares about 45 minutes before the open, already more than the full-day average of about 131,000 shares. The Paris-based biopharmaceutical company said it was working closely with the Food and Drug Administration to resume the trials with an amended protocol, including a lower dosing. The stock, which had closed Friday at a 15-month high, had soared 90% year to date through Friday, while the iShares Nasdaq Biotechnology ETF had rallied 27% and the S&P 500 had climbed 11%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News